Treatment of Refractory Ulcerative Necrobiosis Lipoidica Diabeticorum With Infliximab | Zendy

Stephanie W. Hu | Zendy; Caroline Bevona | Zendy; Laura Winterfield | Zendy; Abrar A. Qureshi | Zendy; Vincent W. Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Refractory Ulcerative Necrobiosis Lipoidica Diabeticorum With Infliximab

Author(s) -

Stephanie W. Hu,

Caroline Bevona,

Laura Winterfield,

Abrar A. Qureshi,

Vincent W. Li

Publication year - 2009

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archdermatol.2009.6

Subject(s) - necrobiosis lipoidica , medicine , dermatology , infliximab , refractory (planetary science) , diabetes mellitus , tumor necrosis factor alpha , physics , astrobiology , endocrinology

Necrobiosis lipoidica diabeticorum (NLD) is a rare, granulomatous inflammatory skin disease of unknown origin, sometimes associated with diabetes mellitus. Skin lesions usually develop on the lower extremities and can progress toward ulceration and scarring. Many treatments have been proposed, but few have demonstrated consistent efficacy, and no standard regimens have emerged to date.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research